http://www.argentisrx.com/content/show.asp?mne=home 11/29/2009 9:12:05 PM http://www.argentisrx.com/content/show.asp?mne=DOCUMENT%5FID%5F304 **Commercial Appeal**: arGentis grew its drug-development pipeline this month with the acquisition of the rights to a rheumatoid arthritis therapy from the University of Tennessee Research Foundation. 11/29/2009 9:12:05 PM http://www.argentisrx.com/content/show.asp?mne=DOCUMENT%5FID%5F300 arGentis announces it will collaborate with the University of Tennessee Health Science Center and the Veterans Affairs Medical Center of Memphis to initiate the first human clinical evaluation of an oral altered peptide ligand (APL), ARG301, in a Phase I study of Rheumatoid Arthritis patients. 11/12/2009 7:04:08 PM http://www.argentisrx.com/content/show.asp?mne=DOCUMENT%5FID%5F297 **Commercial Appeal**: The next trial is the drug's last before it heads to the Food and Drug Administration for market approval. To help that process, arGentis assembled a "dream team" to serve on its scientific advisory board. 11/11/2009 8:37:13 PM http://www.argentisrx.com/content/show.asp?mne=DOCUMENT%5FID%5F296 Maureen D. Mayes, MD, Daniel E. Furst, MD, Virginia D. Steen, MD and Weng Kee Wong, PhD join arGentis' Scientific Advisory Board and will lend expertise in clinical development of ARG201 for Systemic Sclerosis. 10/30/2009 7:40:26 PM http://www.argentisrx.com/content/show.asp?mne=DOCUMENT%5FID%5F293 **Memphis Business Journal**: arGentis is gaining momentum to get its first two therapies to the marketplace with a $10-12 million capital campaign, new paths for clinical trials and a renowned business accelerator firm to help it find a drug development partner. 1/12/2009 9:42:22 PM http://www.argentisrx.com/content/show.asp?mne=DOCUMENT%5FID%5F292 **Commercial Appeal**: arGentis' scleroderma drug wins orphan designation for Europe 1/12/2009 9:39:59 PM http://www.argentisrx.com/content/show.asp?mne=DOCUMENT%5FID%5F287 The article reviews the results of the 168-patient, twelve center trial in which patients were administered a precise dose of highly purified type 1 collagen or placebo for 12 months with follow up at 15 months. 7/6/2008 1:55:33 PM http://www.argentisrx.com/content/show.asp?mne=DOCUMENT%5FID%5F290 **Memphis Business Journal**: Memphis-based arGentis Pharmaceuticals LLC has filed a patent application for a scientific process that will define systemic sclerosis patients that can most benefit from the company's autoimmune therapy. 7/6/2008 1:54:42 PM http://www.argentisrx.com/content/show.asp?mne=DOCUMENT%5FID%5F289 Results from patient DNA samples from a 168-patient, double-blind Phase II trial indicate that 30% of systemic sclerosis patients have a specific nucleotide polymorphism (SNP). 7/6/2008 1:46:37 PM http://www.argentisrx.com/content/show.asp?mne=DOCUMENT%5FID%5F282 The company will target the 40 to 60 million dry eye sufferers in the U.S. and over 100 million people worldwide with the three treatments. 5/12/2008 7:41:02 PM